title: Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?
abstract: Heart failure with preserved ejection fraction, i.e. HFpEF, is highly prevalent in ageing populations, accounting for more than 50 % of all cases of heart failure in Western societies, and is closely associated with comorbidities such as obesity, diabetes and arterial hypertension. However, all large multicentre trials of potential HFpEF treatments conducted to date have failed to produce positive outcomes. These disappointing results suggest that a 'one size fits all' strategy may be ill-suited to HFpEF and support the use of tailored, personalised therapeutic approaches with specific treatments designed for specific comorbidity-related HFpEF phenotypes. The accumulation of a multitude of cardiovascular comorbidities over time leads to increased systemic inflammation, oxidative stress and coronary microvascular endothelial inflammation, eventually resulting in degradation of cyclic guanosine monophosphate (cGMP) via multiple pathways, thereby reducing protein kinase G (PKG) activity. The importance of cGMP-PKG pathway modulation is supported by growing evidence that suggests that this pathway may be a promising therapeutic target, evidence that is mainly based on its role in the phosphorylation of the giant cytoskeletal protein titin. This review will focus on the preclinical and early clinical evidence in the field of cGMP-enhancing therapies and PKG activation.
authors.affiliation: Department of Cardiovascular Physiology, Ruhr University Bochum, Bochum, Germany.
authors.forename: Á
authors.initials: Á
authors.lastname: Kovács
authors.affiliation: Department of Cardiology, Charité Berlin Campus Virchow, Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Alogna
authors.affiliation: Department of Cardiology, Charité Berlin Campus Virchow, Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Post
authors.affiliation: Department of Cardiovascular Physiology, Ruhr University Bochum, Bochum, Germany. nazha.hamdani@rub.de.
authors.forename: N
authors.initials: N
authors.lastname: Hamdani
keywords: Comorbidities; Diastolic stiffness; Heart failure with preserved ejection fraction; Oxidative stress; Titin; cGMP-PKG